Key facts
- This page summarizes Christopher Simon's Form 4 filing for HAEMONETICS CORP (HAE).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 May 2022, 16:26.
Christopher Simon - 16 May 2022 Form 4 Insider Report for HAEMONETICS CORP (HAE)
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- HAE
- Reported as of
- 16 May 2022
- Net transaction value
- -$46,675
- SEC form
- 4
- Accepted by SEC
- 18 May 2022, 16:26:46 UTC
- Prior SEC filing
- 16 Jun 2021
- Next SEC filing
- 23 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas V. Powers, attorney-in-fact for Mr. Simon
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Simon filed Form 4 for HAEMONETICS CORP (HAE) on 18 May 2022.
Change
- Previous filing in this sequence was filed on 16 Jun 2021.
- Current net transaction value: -$46,675.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HAE
transaction
Common Stock
Sale
- Transaction value
- $46,675
- Shares
- -832
- Change %
- -0.43%
- Price
- $56.10
- Shares after
- 191,327
- Date
- 16 May 2022
- Ownership
- Direct
- Footnotes
- F1, F2
HAE
transaction
Common Stock
Award
- Transaction value
- Shares
- +26,041
- Change %
- +14%
- Price
- Shares after
- 217,368
- Date
- 16 May 2022
- Ownership
- Direct
- Footnotes
- F2, F3, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HAE
transaction
Derivative
Non-qualified Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +60,891
- Change %
- Price
- $0.000000
- Shares after
- 60,891
- Date
- 16 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 60,891
- Exercise price
- $57.60
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Footnote F2
This number includes unvested RSUs previously reported as well as 353 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 29, 2022.
Footnote F3
The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.
Footnote F4
Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Footnote F5
Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.